A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine

Bradley A Maron^{1

2}, John J Ryan³

Affiliations

¹ Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (B.A.M.).
² Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.).
³ Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City (J.J.R.).

Bradley A Maron et al. Circulation. 2019.

. 2019 Apr 16;139(16):1861-1864.

doi: 10.1161/CIRCULATIONAHA.118.037613.

Bradley A Maron^{1

2}, John J Ryan³

¹ Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (B.A.M.).
² Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.).
³ Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City (J.J.R.).

No abstract available

Keywords: World Health Organization; endothelin receptor antagonists; heart failure; hypertension, pulmonary; phosphodiesterase 5 inhibitors.

MeSH terms